Steglujan (ertugliflozin;sitagliptin)
- Region
- 🇪🇺 EU
- Active substance
- ertugliflozin;sitagliptin
- Company
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- EU approval
- Fri 23 Mar 2018
- Application
- EMEA/H/C/004313
- ATC
- A10BD24
- Official record
- www.ema.europa.eu
Indication
Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control. in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.
Regulatory milestones
No milestones recorded in the last year.
Follow Steglujan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.